Literature DB >> 2060185

Normal inhibition of mammary tumor metastasis in C3H/He mice.

J Vaage1, D Donovan, T Loftus.   

Abstract

The blood of normal C3H mice contains molecular factors that can rapidly lyse mammary carcinoma cells that enter the circulation. The cytotoxic effect of blood on tumor cells during incubation was most clearly demonstrated if fibrin formation was prevented. The conversion of the mammary carcinoma cells to ascites growth increased both the resistance to lysis in plasma and the ability to form lung colonies after intravenous injection. Mice that were surgically cured of numerous 9 mm tumors and survived for an average 10 months had a lower incidence (36%) of spontaneous metastases than mice that experienced one 30 mm tumor and survived for an average 8 weeks (65%). This is interpreted to mean that mice that retained their vitality by early surgical cures, could suppress the development of metastases by the action of normal serum factors that can destroy neoplastic cells that enter the circulation.

Entities:  

Mesh:

Year:  1991        PMID: 2060185     DOI: 10.1007/bf01753730

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  13 in total

Review 1.  Metastatic inefficiency.

Authors:  L Weiss
Journal:  Adv Cancer Res       Date:  1990       Impact factor: 6.242

2.  Stimulation or inhibition of immune resistance against metastatic or local growth of a C3H mammary carcinoma.

Authors:  J Vaage; S Agarwal
Journal:  Cancer Res       Date:  1976-05       Impact factor: 12.701

3.  The use of replacement transfusion in diseases other than hemolytic disease of the newborn.

Authors:  M BESSIS
Journal:  Blood       Date:  1949-04       Impact factor: 22.113

4.  A survey of in vivo growth characteristics and spontaneous metastasizing potentials of C3H mouse mammary tumors.

Authors:  J Vaage
Journal:  Int J Cancer       Date:  1989-05-15       Impact factor: 7.396

5.  Plasma cell infiltrate of the primary tumor as a source of early systemic protection against metastases in mice.

Authors:  J Vaage; K G Pepin
Journal:  J Natl Cancer Inst       Date:  1983-07       Impact factor: 13.506

6.  Blood component therapy for cancer.

Authors:  B Lichtiger
Journal:  CA Cancer J Clin       Date:  1977 Jul-Aug       Impact factor: 508.702

Review 7.  Nonimmunological host defenses: a review.

Authors:  C A Apffel
Journal:  Cancer Res       Date:  1976-05       Impact factor: 12.701

8.  Non-immunological cell death of intravenously injected murine tumour cells.

Authors:  C J Bishop; K J Donald
Journal:  Br J Exp Pathol       Date:  1979-02

9.  Endogenous tumor growth factor indicated by increased ornithine decarboxylase activity in malignant cells treated with host serum ascites fluid.

Authors:  J Vaage; S Agarwal
Journal:  Cancer Res       Date:  1979-05       Impact factor: 12.701

10.  Multiple cancers. Tumor burden permits the outgrowth of other cancers.

Authors:  C A Mullen; J L Urban; C Van Waes; D A Rowley; H Schreiber
Journal:  J Exp Med       Date:  1985-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.